- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02767661
Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer (MECCA)
February 15, 2024 updated by: wang shusen, Sun Yat-sen University
A Phase 3 Randomized Controlled Study of Metronomic Capecitabine Combined With Aromatase Inhibitor Versus Aromatase Inhibitor Alone for First Line Treatment in Hormone Receptor-positive, Her2-negative Metastatic Breast Cancer
The study is designed to compare the clinical benefit following treatment with aromatase inhibitor in combination with metronomic capecitabine versus aromatase inhibitor alone in women with hormone receptor-positive, Her2-negative advanced breast cancer who have not received prior systemic anti-cancer therapies for their advanced/metastatic disease.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Initial endocrine therapy (ET) is a common choice for hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients for its good tolerability, low toxicity and durable response.
The median time to progression (TTP) of initial ET in HR+, HER2- metastatic patients is about 9 months with aromatase inhibitors (AIs).
However, all metastatic patients receiving ET will develop resistance to the conventional endocrine treatments ultimately.
So some novel agents, like palbociclib and everolimus, are approved to be effective in improving the efficacy of standard ET.
But the fact we have to face is either palbociclib or everolimus is focusing on a single checkpoint of pathway that responsible for resistance of ET.
In clinical, there are some patients without an activation of resistance-related pathways have poor response to endocrine therapy.
And the mechanisms of resistance to endocrine therapy is complicated and not fully understood.
So far, these novel agents have not completely solved the clinical problems of secondary drug-resistance.
Maybe a broad spectrum anti-cancer therapy with low toxicity and good tolerability is more practical and promising in the near future.
Metronomic chemotherapy is administration of low-dose chemotherapy to induce disease control in metastatic cancer patients, which has low-incidence of adverse effects.
More and more evidences showed activity of metronomic therapy in breast cancer.
Metronomic therapy with or without endocrine therapy in both metastatic and neoadjuvant setting showed considerable efficacy.
Although the concept of combination of chemotherapy and endocrine therapy simultaneously was large abandoned because of previous using tamoxifen and intravenous chemotherapy showing no additional benefit, with better understanding of the biology of endocrine therapy and metronomic chemotherapy, it's worth to evaluate whether endocrine therapy plus low-dose metronomic chemotherapy brings a better clinical benefit rate without sacrificing the quality of patients' life.
In this phase III study, we investigate the efficacy and safety of low-dose capecitabine plus AI to treat metastatic HR+, HER2- postmenopausal breast cancer patients.
Study Type
Interventional
Enrollment (Estimated)
240
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adult women with locoregionally recurrent or metastatic disease not amenable to curative therapy
- Confirmed diagnosis of ER positive/Her2-negative breast cancer
- No prior systemic anti-cancer therapy for locoregionally recurrent or metastatic disease
- Any menopausal status, but premenopausal or perimenopausal patients are required to receive LHRHa treatment
- Measurable disease defined by RECIST version 1.1, or bone-only disease
- Eastern Cooperative Oncology Group (ECOG) 0-2, and life expectancy ≥ 3 months
- Adequate organ and marrow function
- Resolution of all toxic effects of prior therapy or surgical procedures
Exclusion Criteria:
- Patients who have progressed within 2 years of adjuvant endocrine therapy
- Patients who have not received prior endocrine therapy and are eligible to receive fulvestrant as initial therapy
- Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term
- Known uncontrolled or symptomatic central nervous system metastases
- Diagnosis of any other malignancy within 3 years prior to randomization (except adequately treated basal or squamous cell skin cancer or cervical carcinoma in situ)
- Serious uncontrolled intercurrent infections or intercurrent medical or psychiatric illness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Aromatase inhibitor
Aromatase inhibitor (Anastrozole 1 mg, orally once daily or Letrozole 2.5mg, orally once daily or Exemestane 25mg, orally once daily)
|
Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)
Other Names:
|
Experimental: Capecitabine+Aromatase inhibitor
Capecitabine, 500mg, orally three times daily in combination with an aromatase inhibitor (Anastrozole 1 mg, orally once daily or Letrozole 2.5mg, orally once daily or Exemestane 25mg, orally once daily)
|
Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)
Other Names:
Capecitabine, 500mg, orally three times daily (continuously)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progress-free survival
Time Frame: Baseline up to approximately 20 months
|
Time from randomization to the first documentation of objective tumor progression or to death due to any cause without documented progression.
|
Baseline up to approximately 20 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: Baseline until death (up to approximately 48 months)
|
Time from randomization to date of death due to any cause.
|
Baseline until death (up to approximately 48 months)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Baseline up to approximately 20 months
|
Objective response is defined as a complete response (CR) or partial response (PR) according to RECIST v.1.1.
recorded from randomization until disease progression or death due to any cause.
|
Baseline up to approximately 20 months
|
Disease Control Rate (DCR)
Time Frame: Baseline up to approximately 20 months
|
Disease control is defined as complete response (CR), partial response (PR), or stable disease (SD) >24 weeks according to the RECIST version 1.1 recorded in the time period between randomization and disease progression or death to any cause.
|
Baseline up to approximately 20 months
|
Adverse events
Time Frame: Baseline up to approximately 20 months
|
Adverse events, serious adverse events, and laboratory tests will be analyzed and summarized according to severity.
|
Baseline up to approximately 20 months
|
Quality-of-life score
Time Frame: Baseline up to approximately 20 months
|
The Functional Assessment of Cancer Therapy - Breast (FACT-B) version 4 questionnaire will be distributed to the patients by the study site personnel and will be filled out by the patients independently.
Final scores (FACT-B-Total) of all subscales range from 0 to 148, where 148 represents the most favorable score and accordingly a highest QoL.
|
Baseline up to approximately 20 months
|
Quality-of-life score
Time Frame: Baseline up to approximately 20 months
|
EORTC QLQ-BR23 questionnaire will be distributed to the patients by the study site personnel and will be filled out by the patients independently.
|
Baseline up to approximately 20 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Shusen Wang, MD, Sun Yat-sen University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 19, 2017
Primary Completion (Estimated)
May 1, 2024
Study Completion (Estimated)
May 1, 2024
Study Registration Dates
First Submitted
May 7, 2016
First Submitted That Met QC Criteria
May 7, 2016
First Posted (Estimated)
May 10, 2016
Study Record Updates
Last Update Posted (Actual)
February 16, 2024
Last Update Submitted That Met QC Criteria
February 15, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Capecitabine
- Letrozole
- Anastrozole
- Exemestane
- Aromatase Inhibitors
Other Study ID Numbers
- SYSUCC 5010-MECCA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Aromatase Inhibitor
-
PfizerCompletedMetastatic Breast CancerSpain, Belgium, Sweden, United Kingdom, Austria, Germany, Switzerland
-
Dartmouth-Hitchcock Medical CenterActive, not recruiting
-
PfizerCompleted
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedHER2/Neu Negative | Stage IV Breast Cancer AJCC v6 and v7 | Estrogen Receptor and/or Progesterone Receptor PositiveUnited States
-
PfizerCompletedMetastatic Breast CancerUnited States
-
Mridula George, MDRecruiting
-
Nemours Children's ClinicNovartis; Pfizer; AstraZeneca; Genentech, Inc.; Thrasher Research FundCompletedIdiopathic Short StatureUnited States, Chile
-
Oklahoma State University Center for Health SciencesActive, not recruiting
-
University of MichiganRecruitingArthralgia | Aging | Breast Neoplasm FemaleUnited States
-
King Faisal Specialist Hospital & Research CenterUnknownAdvanced Breast CancerSaudi Arabia